Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1676
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2487
    -0.0024 (-0.19%)
     
  • Bitcoin GBP

    50,961.15
    -600.15 (-1.16%)
     
  • CMC Crypto 200

    1,326.28
    -70.26 (-5.03%)
     
  • S&P 500

    5,107.41
    +58.99 (+1.17%)
     
  • DOW

    38,287.59
    +201.79 (+0.53%)
     
  • CRUDE OIL

    84.02
    +0.45 (+0.54%)
     
  • GOLD FUTURES

    2,347.30
    +4.80 (+0.20%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.